Glucagon‐like Peptide‐1 Receptor Agonists in Asthma Exacerbations: An Application of High‐Dimensional Iterative Causal Forest to Identify Subgroups
Pharmacoepidemiology and Drug Safety · 2025
DOI: 10.1002/pds.70192 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von Tiansheng Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Asthma, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: The National Institute of Diabetes and Digestive and Kidney Diseases, The North Carolina Translational and Clinical Sciences Institute,, The National Institute of Environmental Health Sciences.
Abstract (Originalsprache)
Background
Glucagon‐like Peptide‐1 Receptor Agonists (GLP1RA) may reduce asthma exacerbation (AE) risk, but it is unclear which populations benefit most. Recent pharmacoepidemiologic studies have employed iterative causal forest (iCF), a machine learning (ML) algorithm, to identify subgroups with heterogeneous treatment effects (HTEs). While iCF does not rely on prior knowledge of treatment‐variable interactions, it may be constrained by missing or poorly defined variables in pharmacoepidemiologic studies.
Methods
We applied the high‐dimensional iterative causal forest (hdiCF)—a causal ML algorithm requiring predefined variables—to MarketScan 2016–2020 claims data to identify populations with asthma that might benefit most from GLP1RA in reducing AE risk. We built a GLP1RA vs. sulfonylurea new‐user cohort with ≥ 1 inpatient or two outpatient asthma encounters, excluding patients with nonasthma indications for systemic steroids. The outcome was acute AE (hospital admission or emergency department visit for asthma), assessed over 6 months using 599 high‐dimensional features from inpatient/outpatient services and pharmacy claims.
Results
In the overall population, GLP1RA decreased AE risk relative to sulfonylurea: aRD −1.4% (−2.0%, −0.8%). hdiCF identified three subgroups based on the quantity of systemic steroid prescription fills (0, 1, and ≥ 2): patients with ≥ 2 prescriptions (GLP1RA: 34 events/1367 individuals; sulfonylurea: 53/1013) benefited most from GLP1RA: aRD −3.8% (−5.3%, −2.2%).
Conclusions
This study demonstrates how automated feature identification can pinpoint clinically relevant subgroups with HTEs. The quantity of systemic steroid prescriptions, as a proxy for severe asthma, may guide personalized predictions of GLP1RA's short‐term benefits on acute AE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, North Carolina, USA.
- Department of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA.
- Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, New Jersey, USA.
- Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
- Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
ORCID-Profile: Tiansheng Wang, Alan C Kinlaw, Virginia Pate, John B Buse, Corinne A Keet, Michael R Kosorok, Til Stürmer
Förderung
- The National Institute of Diabetes and Digestive and Kidney Diseases
- The North Carolina Translational and Clinical Sciences Institute,
- The National Institute of Environmental Health Sciences
- NIEHS NIH HHS
- NCATS NIH HHS
- American Diabetes Association
- NCI NIH HHS
- The National Institute on Aging
Zitieren
APA
Wang, T., Wang, J. H., Kinlaw, A. C., Wyss, R., Pate, V., Gou, Z., Buse, J. B., Keet, C. A., Kosorok, M. R., & Stürmer, T. (2025). Glucagon‐like Peptide‐1 Receptor Agonists in Asthma Exacerbations: An Application of High‐Dimensional Iterative Causal Forest to Identify Subgroups. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70192
Vancouver
Wang T, Wang JH, Kinlaw AC, Wyss R, Pate V, Gou Z, et al. Glucagon‐like Peptide‐1 Receptor Agonists in Asthma Exacerbations: An Application of High‐Dimensional Iterative Causal Forest to Identify Subgroups. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70192
BibTeX
@article{Wang2025,
author = {Wang, Tiansheng and Wang, Jeanny H and Kinlaw, Alan C and Wyss, Richard and Pate, Virginia and Gou, Zhuoyue and Buse, John B and Keet, Corinne A and Kosorok, Michael R and Stürmer, Til},
title = {Glucagon‐like Peptide‐1 Receptor Agonists in Asthma Exacerbations: An Application of High‐Dimensional Iterative Causal Forest to Identify Subgroups},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2025},
doi = {10.1002/pds.70192}
}
EUVIMED